A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)
Status:
Completed
Trial end date:
1990-04-01
Target enrollment:
Participant gender:
Summary
To determine the effectiveness and safety of dextran sulfate (DS) as a treatment for patients
with AIDS, AIDS related complex (ARC), or asymptomatic HIV infection with or without
persistent generalized lymphadenopathy (PGL), and to determine antiviral activity at
different doses of DS. Although zidovudine (AZT) has shown promise in prolonging life in
patients with AIDS and severe ARC, it has significant blood toxicities. It would be
beneficial to combine AZT with another antiviral agent that does not have the same toxicity.
DS might be a suitable drug since it has shown antiviral activity against HIV in the
laboratory, and in preliminary studies it has shown little toxicity. Also, the combination of
DS with AZT has been shown to be more effective than either alone.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)